|Articles|January 15, 2002
CDC focuses on medical response to bioterrorism threat
Baltimore-The Centers for Disease Control and Prevention (CDC) has been at the forefront of the medical response to the bioterrorism threat in recent months since the first case of inhalation anthrax was identified.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5











































.png)


